Screener / SEC EDGAR /CIK 0001609550 /10-K filed Feb 13, 2026, compared with Feb 10, 2025 /Numbers from the XBRL of the 10-Ks
NYSE Health care · Medical Instruments

Inspire Medical Systems, Inc. INSP

Compare with peers Embed
SEC comment letters, last 20 years

1 review of INSP's filings by SEC staff

UPLOAD and CORRESP
Reviews 1 latest letter Mar 13, 2018
Questions asked 10 each answered in the company's own letter
No closing letter 1 reviews without a letter saying the staff completed it

When the SEC's staff reviews a filing, it writes to the company with numbered questions, and the company answers each one in a letter. SEC publishes the exchange once the review is over, at least 20 business days later. A question is not an accusation; most reviews end with the company adding detail to its next filing.

How the reviews went

Every review on EDGAR, from the first staff letter to the letter that closes it

  1. 1. Staff letters 1 UPLOAD
  2. 2. Questions in them 10 numbered comments
  3. 3. Company replies 1 CORRESP
  4. 4. Reviews closed 0 of 1 closing letter

Form S-1

2018-03-13 to 2018-04-13 · 10 questions · 1 letter from the SEC, 1 from the company
No closing letter
Risk factorsReserves and insurance
Overview, page 1
SEC asked (1)
Expand the disclosure in the first paragraph of this section to disclose that the approval is for specific indications as mentioned in the first risk factor on page 33 and briefly describe the specific indications.
INSP answered
On behalf of Inspire Medical Systems, Inc. (the “Company”), we are providing the staff (the “Staff”) of the Division of Corporation Finance of the Securities and Exchange Commission (the “Commission”) with a supplemental submission regarding the proposed disclosure of the Company’s estimated results for the quarter ended March 31, 2018. We have attached as Exhibit A to this letter a draft of the “Prospectus Summary—Preliminary Financial Results for the First Quarter Ended March 31, 2018” section that presents a range of the Company’s estimated revenue, gross margin, operating loss and net loss for the three months ended March 31, 2018, compared to the Company’s revenue, gross margin,
Rest of the letter

operating loss and net loss for the three months ended March 31, 2017, and the Company’s estimated cash, cash equivalents and short-term investments and principal and interest outstanding under its credit facility as of March 31, 2018. The Company expects to provide this information to potential investors by including it in the preliminary prospectus for the Company’s initial public offering.

One letter for all the questions, without numbered answers. Read the reply
Overview, page 1
SEC asked (2)
Please tell us whether the peer-reviewed articles that you reference are based upon data provided by you or by unrelated third parties. Also, tell us whether there are other peerreviewed articles or other information available about your system, especially those that address any negative findings relating to your system.
INSP answered

See the reply above.

Our Market Opportunity, page 2
SEC asked (3)
Clearly explain each step you must take to commercialize your technology, including the material hurdles you must overcome at relevant junctures. If such information is appropriate for your prospectus summary, carefully consider the information that is the most significant, and briefly highlight that information in the summary and include more detailed disclosure elsewhere in your prospectus.
INSP answered

See the reply above.

Significant body of strong clinical data, page 4
SEC asked (4)
You disclose that four sponsored and more than five independent clinical studies have evaluated more than 750 patients using your treatment. Please clarify how many patients were evaluated in connection with independent studies.
INSP answered

See the reply above.

Implications of Being an Emerging Growth Company, page 6
SEC asked (5)
Please supplementally provide us with copies of all written communications, as defined in Rule 405 under the Securities Act, that you or anyone authorized to do so on your behalf, present to potential investors in reliance on Section 5(d) of the Securities Act, whether or not they retain copies of the communications.
INSP answered

See the reply above.

Market and Industry Data, page 57
SEC asked (6)
Tell us whether you commissioned any of the data that you attribute to third parties in your registration statement.
INSP answered

See the reply above.

Market and Industry Data, page 57
SEC asked (7)
We note your statement that information in the prospectus is based on industry and general publications and research, surveys and studies conducted by third parties which you have not independently verified. You are responsible for the entire content of the registration statement and should not include language that can be interpreted as a disclaimer of information you have chosen to include. Please revise.
INSP answered

See the reply above.

Use of Proceeds, page 58
SEC asked (8)
Disclose the approximate amount of proceeds that you currently intend to use for each purpose mentioned in the second paragraph on page 58. You may reserve the right to change the use of proceeds as described in Instruction7 to Item 504 of Regulation S-K.
Rest of the question

If you have no current specific plan for the proceeds, or a significant portion of the proceeds, please say so directly and discuss the principal reasons for this offering.

INSP answered

See the reply above.

Government Regulation, page 108
SEC asked (9)
Clarify in which jurisdictions you have received the regulatory clearances necessary for your system to be sold.
INSP answered

See the reply above.

Management, page 122
SEC asked (10)
Ensure that your disclosure provides the five year background with all information required by Item 401(e) of Regulation S-K. For example, disclose when Mr. McCormick served on the board of directors of Entellus, Nevro and Surmodics.
INSP answered

See the reply above.

Letters without questions

Other letters

UPLOAD and CORRESP
5 other letters: notices that a filing will not be reviewed, requests to declare a registration effective, and the like

From the SEC's correspondence on EDGAR: staff letters (form UPLOAD) and company letters (form CORRESP), 7 letters filed since 2018-03-13. Questions and answers are matched by their numbers; topics come from words in each question. The reports are compared word for word (same form, before the first SEC letter against the first report after the company's reply). No AI.

Sources

The SEC's correspondence on EDGAR: staff letters (form UPLOAD) and company letters (form CORRESP), matched question by question. No AI.

Also

Filings: the letters in the filing list.

Work with it

Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/INSP/export.csv") into a cell.

Next in Owners and insiders:Insider trades
Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.